Gemma Frisius Fund is a seed capital fund established as a joint venture between KU Leuven, KBC Group, and BNP Paribas Fortis Private Equity to stimulate the creation and growth of KU Leuven spin-off companies. It provides seed and start-up capital to spin-offs commercializing knowledge and research developed at KU Leuven.
43% of their portfolio is in Biotech & Life Sciences. They made 1 investments in the last 12 months. Their most common stage is seed (43% of deals).
Portfolio
7
Fund Size
—
Top Stage
Seed
Last 12 Mo
1
Team
PV
Paul Van Dun
Managing Director
RC
Rudi Cuyvers
Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| RRuneasi | Seed | — | Feb 2026 |
 Obulytix | Seed | — | Dec 2023 |
 REIN4CED | Series B | — | Jan 2021 |
| OOkapi Sciences | Unknown | — | Nov 2008 |
 Aspect Analytics | Series A | — | — |
 Ugentec | Seed | $9.3M | — |
| DDname-iT | Unknown | — | — |
Top Co-Investors
PMV2 shared
Angel Invest1 shared
ArcTern Ventures1 shared
Qbic1 shared
Finindus1 shared
imec.istart1 shared
Thuja Capital1 shared
Martlet1 shared
Last updated: 9 September 2026